These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 11503786)

  • 1. Efavirenz: new preparation. An alternative to HIV protease inhibitors.
    Prescrire Int; 2000 Apr; 9(46):46-9. PubMed ID: 11503786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance.
    Prescrire Int; 2001 Jun; 10(53):70-2. PubMed ID: 11718166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination.
    James JS
    AIDS Treat News; 1998 Jul; (No 299):1-3. PubMed ID: 11365599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dressing up your virus: a new outfit for HIV.
    Simmons P
    Res Initiat Treat Action; 1998 Aug; 4(5):9. PubMed ID: 11365710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nevirapine: new preparation. In second-line triple-drug anti-HIV regimens.
    Prescrire Int; 1998 Oct; 7(37):140-1. PubMed ID: 10915417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiretroviral therapy 2001. Basic principles and current status].
    Jablonowski H
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():4-12. PubMed ID: 11373777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trials for protease failure.
    Posit Aware; 1998; 9(5):16-7. PubMed ID: 11365884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crixivan (Indinavir): three doses daily, not two, in most regimens.
    James JS
    AIDS Treat News; 1998 Oct; (No 304):4-5. PubMed ID: 11365863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():37-8. PubMed ID: 11373775
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antiretroviral therapy. Update at the beginning of a new century].
    Jablonowski H
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():5-13. PubMed ID: 10863303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz (SUSTIVA, formerly DMP-266) 48-week data announced.
    AIDS Treat News; 1997 Sep; (No 279):2-3. PubMed ID: 11364690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz in the management of HIV infection.
    Gazzard BG
    Int J Clin Pract; 1999; 53(1):60-4. PubMed ID: 10344069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.